source
- FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravisThe FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…
- FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolioRegeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…